CAR T-Cell, An Issue of Hematology/Oncology Clinics of North America
- 1st Edition, Volume 37-6 - October 12, 2023
- Imprint: Elsevier
- Editors: Caron A Jacobson, Parth S. Shah
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 1 8 3 0 0 - 3
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 8 3 0 1 - 0
In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top… Read more
Purchase options
In this issue of Hematology/Oncology Clinics, guest editors Drs. Caron A. Jacobson and Parth S. Shah bring their considerable expertise to the topic of CAR T-Cell Therapy. Top experts in the field discuss the multiple ways CAR T-cell therapy can be used to help fight a variety of cancers, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia (ALL).
- Contains 12 practice-oriented topics including CAR T-cells in aggressive B-cell lymphomas; CAR T-cells in multiple myeloma; CAR T-cells in AML; mechanisms of resistance of CAR T-cell therapy; the role of CAR T-cell therapy in the era of bispecific antibodies; and more.
- Provides in-depth clinical reviews on CAR T-cell, offering actionable insights for clinical practice.
- Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
Hematology, oncology
The Current State of Chimeric Antigen Receptor T Cell Therapy for B Lymphoblastic Leukemia
Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma
Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
Chimeric Antigen Receptor T Cells in Multiple Myeloma
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas
Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
Early and Late Toxicities of Chimeric Antigen Receptor T-Cells
Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies
The Future of Chimeric Antigen Receptor T Cell Therapy
Chimeric Antigen Receptor T-Cell Therapy in Aggressive B-Cell Lymphoma
Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
Chimeric Antigen Receptor T Cells in Multiple Myeloma
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas
Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors
Early and Late Toxicities of Chimeric Antigen Receptor T-Cells
Mechanisms of Resistance to Chimeric Antigen Receptor T Cell Therapy
The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies
The Future of Chimeric Antigen Receptor T Cell Therapy
- Edition: 1
- Volume: 37-6
- Published: October 12, 2023
- Imprint: Elsevier
- Language: English
CJ
Caron A Jacobson
Affiliations and expertise
Harvard Medical SchoolPS
Parth S. Shah
Affiliations and expertise
Assistant Professor of Medicine, Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Director of Genome Informatics, Dartmouth-Hitchcock, Transplant and CAR-T, Dana-Farber Cancer Institute